BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35432200)

  • 1. Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas.
    Giuffrida G; D'Argenio V; Ferraù F; Lasorsa VA; Polito F; Aliquò F; Ragonese M; Cotta OR; Alessi Y; Oteri R; Di Maggio F; Asmundo A; Romeo PD; Spagnolo F; Pastore L; Angileri FF; Capasso M; Cannavò S; Aguennouz M
    Front Endocrinol (Lausanne); 2022; 13():841118. PubMed ID: 35432200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
    Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
    J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Methylome and Transcriptome Signatures Expands the Molecular Classification of the Pituitary Tumors.
    Silva-Júnior RMPD; Bueno AC; Martins CS; Coelli-Lacchini F; Ozaki JGO; Almeida-E-Silva DC; Marrero-Gutiérrez J; Santos ACD; Garcia-Peral C; Machado HR; Santos MVD; Elias PL; Moreira AC; Colli LM; Vêncio RZN; Antonini SR; de Castro M
    J Clin Endocrinol Metab; 2023 May; 108(6):1452-1463. PubMed ID: 36504388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma.
    Ashton C; Rhie SK; Carmichael JD; Zada G
    J Neurosurg; 2020 Feb; 134(3):787-793. PubMed ID: 32109873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation profiling in nonfunctioning pituitary adenomas.
    Kober P; Boresowicz J; Rusetska N; Maksymowicz M; Goryca K; Kunicki J; Bonicki W; Siedlecki JA; Bujko M
    Mol Cell Endocrinol; 2018 Sep; 473():194-204. PubMed ID: 29410024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.
    Vicchio TM; Aliquò F; Ruggeri RM; Ragonese M; Giuffrida G; Cotta OR; Spagnolo F; Torre ML; Alibrandi A; Asmundo A; Angileri FF; Esposito F; Polito F; Oteri R; Aguennouz MH; Cannavò S; Ferraù F
    J Endocrinol Invest; 2020 Jul; 43(7):947-958. PubMed ID: 31939196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.
    Gejman R; Batista DL; Zhong Y; Zhou Y; Zhang X; Swearingen B; Stratakis CA; Hedley-Whyte ET; Klibanski A
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4119-25. PubMed ID: 18628527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas.
    He Z; Chen L; Hu X; Tang J; He L; Hu J; Fei F; Wang Q
    Endocr J; 2019 Aug; 66(8):709-722. PubMed ID: 31061247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of microRNAs in GH-secreting pituitary adenomas.
    Mao ZG; He DS; Zhou J; Yao B; Xiao WW; Chen CH; Zhu YH; Wang HJ
    Diagn Pathol; 2010 Dec; 5():79. PubMed ID: 21138567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.
    Diaz-Rodriguez E; Garcia-Rendueles AR; Ibáñez-Costa A; Gutierrez-Pascual E; Garcia-Lavandeira M; Leal A; Japon MA; Soto A; Venegas E; Tinahones FJ; Garcia-Arnes JA; Benito P; Angeles Galvez M; Jimenez-Reina L; Bernabeu I; Dieguez C; Luque RM; Castaño JP; Alvarez CV
    Endocrinology; 2014 Nov; 155(11):4329-40. PubMed ID: 25137025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-functioning pituitary adenomas: growth and aggressiveness.
    Øystese KA; Evang JA; Bollerslev J
    Endocrine; 2016 Jul; 53(1):28-34. PubMed ID: 27066792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential gene expression of sirtuins between somatotropinomas and nonfunctioning pituitary adenomas.
    Grande IPP; Amorim PVGH; Freire ACTB; Jallad RS; Musolino NR; Cescato VA; da Silva GO; Bronstein MD; Trarbach EB
    Pituitary; 2018 Aug; 21(4):355-361. PubMed ID: 29564694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
    Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
    Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
    Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.
    Shirian FI; Ghorbani M; Khamseh ME; Imani M; Panahi M; Alimohammadi A; Nourbakhsh M; Salimi V; Tavakoli-Yaraki M
    BMC Endocr Disord; 2021 Mar; 21(1):50. PubMed ID: 33736633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recognition of aggressive pituitary adenomas: a single-centre experience.
    Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
    Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing the outcome of microsurgical transsphenoidal surgery for pituitary adenomas: a study on 184 patients.
    Lampropoulos KI; Samonis G; Nomikos P
    Hormones (Athens); 2013; 12(2):254-64. PubMed ID: 23933694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.
    Ruebel KH; Jin L; Zhang S; Scheithauer BW; Lloyd RV
    Endocr Pathol; 2001; 12(3):281-9. PubMed ID: 11740049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.